OBJECTIVES : To describe and characterize health-related quality of life (HRQOL) as measured by the EQ-5D-5L among patients with early-stage HR+/HER2- breast cancer across clinically relevant patient sub-groups.

METHODS : A multinational (France, Germany, Italy, Japan, Spain, UK and US) survey of patients with stage I-III HR+/HER2- breast cancer, either receiving adjuvant treatment or under surveillance, was performed from June to October 2019. Patients meeting these criteria were identified through their consulting physician, who invited them to complete a pen and paper questionnaire. HRQOL was measured through patient completed EQ-5D-5L questionnaires. EQ-5D index scores were derived using available country-specific health state value sets. Descriptive summary statistics were reported for index and VAS scores for each country, age groups at time of PRO completion, and adjuvant treatment status (active treatment vs. surveillance).

RESULTS : Among 2,327 patients identified, 1,122 (48%) completed an accompanying patient self-completion form (mean age 59 years, 78% actively receiving adjuvant therapy, stage at diagnosis: 31% stage I, 48% stage II, 20% stage III, 1% stage unknown). Overall, unadjusted mean utilities among patients ranged from 0.836 (active treatment) to 0.851 (surveillance), and by age from 0.875 (25-34) to 0.734 (75+) and by country from 0.876 (UK) to 0.757 (France). Mean VAS scores ranged from 74.9 (active treatment) to 74.5 (surveillance), by age from 78.9 (25-34) to 69.3 (75+) and by country from 78.9 (UK) to 68.0 (Germany).

CONCLUSIONS : Overall HRQOL among breast cancer disease-free patients was high. These results improve our understanding of baseline HRQOL among patients with early disease and may facilitate future studies examining the impact of disease recurrence, including metastasis.